* MIDAZOLAM NASAL SPRAY HAS ALSO BEEN GRANTED FAST TRACK DESIGNATION BY THE US FDA DUE TO THE HIGH UNMET NEED FOR PATIENTS AND CAREGIVERS * MIDAZOLAM NASAL SPRAY HAS BEEN GRANTED ORPHAN DRUG ...
MedPage Today on MSN
Trial Questions Ketamine Use for Patients Hospitalized With Depression
A 2022 study showed that 28.3% of patients receiving ketamine had a billing diagnosis of depression. McLoughlin's group ...
By Dennis Thompson HealthDay ReporterTUESDAY, Oct. 28, 2025 (HealthDay News) — Ketamine might not be effective in treating ...
Alert FDA OKs Midazolam Nasal Spray (Nayzilam) for Seizure Clusters Nayzilam is the first FDA-approved nasal option for treating seizure clusters that are distinct from a patient's usual seizure ...
The Phase 3 open-label extension (OLE) study evaluated the safety of repeated, intermittent use of NAYZILAM in individuals living with epilepsy experiencing acute repetitive seizures, also known as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback